Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 24.29% and Operating profit at 13.72% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 5.07% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 24.29% and Operating profit at 13.72% over the last 5 years
3
Positive results in Sep 25
4
With ROE of 5.58%, it has a fair valuation with a 0.45 Price to Book Value
5
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,096 Million (Small Cap)
8.00
NA
0.00%
0.29
5.99%
0.60
Revenue and Profits:
Net Sales:
597 Million
(Quarterly Results - Sep 2025)
Net Profit:
43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.18%
0%
14.18%
6 Months
44.35%
0%
44.35%
1 Year
142.81%
0%
142.81%
2 Years
130.24%
0%
130.24%
3 Years
37.23%
0%
37.23%
4 Years
-11.56%
0%
-11.56%
5 Years
0%
0%
0.0%
Wuhan Huakang Century Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
24.29%
EBIT Growth (5y)
13.72%
EBIT to Interest (avg)
28.02
Debt to EBITDA (avg)
1.45
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
0.68
Tax Ratio
16.79%
Dividend Payout Ratio
7.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.66%
ROE (avg)
5.07%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
0.45
EV to EBIT
8.87
EV to EBITDA
6.80
EV to Capital Employed
0.58
EV to Sales
0.67
PEG Ratio
0.25
Dividend Yield
NA
ROCE (Latest)
6.55%
ROE (Latest)
5.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
596.60
525.70
13.49%
Operating Profit (PBDIT) excl Other Income
50.50
56.30
-10.30%
Interest
8.80
5.60
57.14%
Exceptional Items
0.00
0.00
Consolidate Net Profit
42.90
30.30
41.58%
Operating Profit Margin (Excl OI)
84.60%
79.60%
0.50%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 13.49% vs 16.28% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 41.58% vs -17.44% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,701.60
1,598.30
6.46%
Operating Profit (PBDIT) excl Other Income
136.00
145.20
-6.34%
Interest
23.60
11.40
107.02%
Exceptional Items
0.80
0.00
Consolidate Net Profit
66.70
107.30
-37.84%
Operating Profit Margin (Excl OI)
53.10%
75.10%
-2.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.46% vs 35.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -37.84% vs 4.68% in Dec 2023
About Wuhan Huakang Century Medical Co., Ltd. 
Wuhan Huakang Century Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






